Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Equity Income (2019 - 2026)

Neurocrine Biosciences filings provide 7 years of Equity Income readings, the most recent being $2.7 million for Q4 2025.

  • On a quarterly basis, Equity Income rose 242.11% to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.0 million, a 89.22% increase, with the full-year FY2025 number at -$4.0 million, up 89.22% from a year prior.
  • Equity Income hit $2.7 million in Q4 2025 for Neurocrine Biosciences, down from $30.6 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $37.3 million in Q2 2023 to a low of -$40.1 million in Q3 2023.
  • Median Equity Income over the past 5 years was $1.6 million (2024), compared with a mean of $2.1 million.
  • Biggest five-year swings in Equity Income: skyrocketed 2742.86% in 2022 and later crashed 2012.5% in 2025.
  • Neurocrine Biosciences' Equity Income stood at $28.4 million in 2021, then plummeted by 74.65% to $7.2 million in 2022, then surged by 302.78% to $29.0 million in 2023, then crashed by 106.55% to -$1.9 million in 2024, then surged by 242.11% to $2.7 million in 2025.
  • The last three reported values for Equity Income were $2.7 million (Q4 2025), $30.6 million (Q3 2025), and -$6.7 million (Q2 2025) per Business Quant data.